Lumen Therapeutics LLC is categorized under Commercial Medical Research in Menlo Park, CA and active since 2003.
Lumen Therapeutics LLC was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Paul Mcgrane at the company’s single location by writing to 325 Sharon Park Drive # 753, Menlo Park, California CA 94025 or by phoning (650) 450-4439. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lumen Therapeutics LLC |
| Contact Person: | Paul Mcgrane |
| Address: | 325 Sharon Park Drive # 753, Menlo Park, California 94025 |
| Phone Number: | (650) 450-4439 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Lumen Therapeutics LLC was started in 2003 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Paul Mcgrane for inquiries that concern Lumen Therapeutics LLC by calling the company number (650) 450-4439, as your correspondence is most welcome. Additionally, the physical location of the single location of Lumen Therapeutics LLC can be found at the coordinates 37.42424,-122.197451 as well as the street address 325 Sharon Park Drive # 753 in Menlo Park, California 94025.
For its online presence, you may visit Lumen Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.